Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138230 | 0.89 | PTPN1 (0.43) | PTPN1PTPN2MEN1KMT2ADYRK1A | |
| SCHEMBL5364403 | 0.85 | KMT2A (0.56) | MEN1KMT2ADYRK1AALDH1A1LMNA | |
| SCHEMBL5367431 | 0.85 | RET (0.55) | PTPN1PTPN2MEN1KMT2ADYRK1A | |
| SCHEMBL7135682 | 0.82 | PTPN1 (0.38) | PTPN1PTPN2MEN1KMT2ADYRK1A | |
| SCHEMBL5366590 | 0.79 | MEN1 (0.55) | MEN1KMT2ADYRK1AALDH1A1LMNA | |
| SCHEMBL5358671 | 0.78 | RET (0.39) | PTPN1MEN1KMT2ADYRK1AALDH1A1 | |
| SCHEMBL7137405 | 0.77 | IGF1R (0.45) | MEN1KMT2ARETMAPT | |
| SCHEMBL5370157 | 0.76 | EGFR (0.58) | MEN1KMT2AALDH1A1POLBRET | |
| SCHEMBL5372795 | 0.74 | PIM1 (0.45) | PTPN1PTPN2MEN1KMT2ADYRK1A | |
| SCHEMBL5368693 | 0.74 | MAPT (0.39) | PTPN1MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PTPN1 882/4885PTPN2 1051/4885MEN1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.